Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Cymabay Therapeutics (CBAY)

Pharmaceutical Preparations

https://www.cymabay.com

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

7575 GATEWAY BOULEVARD, SUITE 110
NEWARK, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/15/2014

Market Cap

3,728,216,800

Shares Outstanding

113,400,000

Weighted SO

113,403,353

Total Employees

N/A

Upcoming Earnings

05/20/2024

Similar Tickers

DAWN --.--%

XFOR --.--%

INZY --.--%

ABOS --.--%

MREO --.--%

AKRO --.--%

TERN --.--%

MDGL --.--%

VKTX --.--%

Beta

0.3200

Last Div

0.0000

Range

7.261-32.5

Chg

0.0100

Avg Vol

3944615

Mkt Cap

3728216800

Exch

NASDAQ

Country

US

Phone

510 293 8800

DCF Diff

27.6296

DCF

4.8504

Div Yield

0.0000

P/S

119.9825

EV Multiple

-38.3547

P/FV

12.5942

Div Yield %

0.0000

P/E

-32.9591

PEG

-1.2360

Payout

0.0000

Current Ratio

10.9601

Quick Ratio

10.7009

Cash Ratio

5.6058

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

2051.7181

CCC

-2051.7181

Gross Margin

0.9781

Op Margin

-3.2723

Pretax Margin

-3.3910

Net Margin

-3.5940

Eff Tax Rate

-0.1138

ROA

-0.2569

ROE

-0.5375

ROCE

-0.2556

NI/EBT

1.0598

EBT/EBIT

1.0363

EBIT/Rev

-3.2723

Debt Ratio

0.2512

D/E

0.3736

LT Debt/Cap

0.2534

Total Debt/Cap

0.2720

Int Coverage

-10.9816

CF/Debt

-0.6643

Equity Multi

1.4873

Rec Turnover

0.0000

Pay Turnover

0.1779

Inv Turnover

0.0000

FA Turnover

5.4276

Asset Turnover

0.0715

OCF/Share

-0.6400

FCF/Share

-0.6440

Cash/Share

3.4790

OCF/Sales

-2.3342

FCF/OCF

1.0061

CF Coverage

-0.6643

ST Coverage

-7.2480

CapEx Coverage

-162.9910

Div&CapEx Cov

-162.9910

P/BV

12.5942

P/B

12.5942

P/S

119.9825

P/E

-32.9591

P/FCF

-51.0883

P/OCF

-50.7472

P/CF

-50.7472

PEG

-1.2360

P/S

119.9825

EV Multiple

-38.3547

P/FV

12.5942

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 16, 16:28 CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga Dec 15, 15:00 6 Analysts Have This to Say About CymaBay Therapeutics GlobeNewswire Inc. Nov 17, 16:15 CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revenue Product Segmentation